Last reviewed · How we verify
NVL-655
At a glance
| Generic name | NVL-655 |
|---|---|
| Also known as | Neladalkib |
| Sponsor | Nuvalent Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC (PHASE3)
- Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors
- A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NVL-655 CI brief — competitive landscape report
- NVL-655 updates RSS · CI watch RSS
- Nuvalent Inc. portfolio CI